The Global Strategy for Tuberculosis Research and Innovation will support the efforts of governments and other stakeholders to accelerate TB research and innovation, and improve equitable access to the benefits of research.
Availabl in Arabic, Chinese, English, French, Spanish and Russian
The content of the tool has been updated to reflect new WHO technical guidance and new evidence on both COVID-19 pandemic and mass gatherings, as well as feedback from end-users. This revision of the risk assessment tool was developed and reviewed by the WHO Mass Gathering Technical Expert Group wit...h input from WHO area-specific technical teams. The expanded tool includes eight tabs: 1. Instructions; 2. Assessment Overview; 3. Decision Tree; 4. Risk Evaluation; 5. Risk Mitigation; 6. Decision Matrix; 7. Risk Communication; and 8. Reviewer Sign Off. There as an additional tab with a glossary and list of abbreviations.
more
Risk of spill-over of EVD to Uganda has been categorised as very high. On 28 September 2018, WHO elevated the risk at the regional level which includes Uganda from ‘high’ to ‘very high’. Uganda has a very long and largely porous border with the DRC. High population movements across the borde...rs occur for various reason including for trade, social activities and services and asylum. There are cross-border markets in several border districts in Uganda and DRC that involve thousands of people crossing into and out of DRC and Uganda for trade purposes several days in a week.
more
Documento de informação sintético
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...ed: version 15 March 2022.
more
Interim guidanceAnnex to: Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021
Surveillance of antimicrobial resistance in Europe 2020 data: executive summary
Verstädterung, Flächennutzung, globaler Handel und Industrialisierung haben auf der ganzen Welt tiefgreifende negative Folgen für Natur, Biodiversität und Ökosysteme. Der fortwährende Abbau natürlicher Ressourcen wirkt sich nicht nur auf den Zustand der Umwelt aus, sondern hat auch enorme Aus...wirkungen für Wohlergehen und Sicherheit der Gesellschaften. Dieser Bericht bietet eine Übersicht der vielfältigen Einwirkung der natürlichen Umwelt auf die menschliche Gesundheit. Er legt dar, wie Natur und Ökosysteme Gesundheit und Wohlbefinden unterstützen und schützen können und wie zugleich die Zerstörung der Natur und der Verlust an Biodiversität die menschliche Gesundheit bedrohen. Er ist an ein Publikum gerichtet, das nicht über umfassende Erfahrung mit den Verbindungen zwischen Natur und Gesundheit verfügt. Diese Übersicht richtet sich in erster Linie an Personen, die sich beruflich oder politisch mit Umwelt und Gesundheit beschäftigen, kann aber auch für andere Bereiche relevant sein, die mit dem Schutz, der Handhabung und der Nutzung von Natur und Biodiversität befasst sind.
more
1PEP GUIDELINES | 2019 EDITION. The prevalence of both HIV and Hepatitis B is high in South Africa therefore there is a significant risk of acquiring these infections following exposure to infected material. Studies suggest that post- exposure prophylaxis (PEP) with highly active antiretroviral trea...tment (HAART) is highly effective in preventing HIV infection if taken correctly for the full recommended duration of 28 days, and that prophylaxis with Hepatitis B immunoglobulin and vaccination may prevent Hepatitis B infection if given soon after exposure. This update of the Western Cape guidelines for management of potentially infectious exposures is based on current evidence and guidelines issued by the WHO, NDoH and the SA HIV Clinicians Society. The key aim is to promote successful completion of the recommended ART regimen in the 28 day period of therapy, as well as prevent infection with Hepatitis B
more
Fact Book on WHO Level I and Level II monitoring indicators - To monitor the progress of efforts to improve the global medicines situation, WHO has developed a system of indicators that measure important aspects of a country’s pharmaceutical situation. Level 1 indicators measure the existence and ...performance of key national pharmaceutical structures and processes. Level II indicators measure key outcomes of these structures and processes in the areas of access, product quality and rational use. These indicators can be used to assess progress over time; to compare situations between countries; and to reassess and prioritize efforts based on the results.
This Fact Book gives the results of the assessment of Level I indicators conducted in 2003 and of Level II indicator surveys conducted between 2002 and 2004
more